Index

Abbreviations:
- CIM: complementary and integrative medicine
- HSCT: hematopoietic stem cell transplantation
- NSCLC: non-small-cell lung cancer
- PROs: patient-reported outcomes
- PSA: prostate-specific antigen
- RCTs: randomized controlled trials
- TKIs: tyrosine kinase inhibitors
- TRUS: transrectal ultrasonography

Note:
Index entries beginning ‘cancer’ have been kept to a minimum, and readers are advised to seek more specific entries (e.g., diagnosis of cancer).

Page 437

© 2018 The American Cancer Society. Published 2018 by John Wiley & Sons, Inc.
Ames test 140
aminopterin 236, 238
anal cancer, sexual dysfunction 360, 364
analgésia, cancer pain 344, 344–345
anaphylactic reactions, to chemotherapy 402
anaplastic lymphoma kinase (ALK) 274, 275, 312
astrozole 236, 238
androgen(s) 239
receptors 239
androgen deprivation therapy (ADT) 360, 363
late effects 422–423
prostate cancer therapy 239, 360, 363
anemia 346
angiogenesis 139, 147, 276–277
critical step in tumor progression 276
induction 147–148, 149
inhibition/inhibitors 147, 148, 276–277
mechanisms 147, 148
targeted therapy 276–277
clinical experience 276–277
preclinical studies 276
angiogenic factors 276
angiogenesis inhibitors 104
angiostatin 148
angiotensin-converting enzyme (ACE) inhibitors 104
anthracyclines 231
anemia 346
chemotherapeutic agents 346
chemotherapy 231
angiogenesis inhibitors 104
anemia, chronic 384
HR 383
epidemiology 99–100
host phenotype 101–102
incidence and burden 100, 101
mortality 99
prevention 103
risk factors 100, 102
trials 385
tanning beds 100–101
base excision repair (BER) 143, 143, 144
base memorial, degradation 148
"basket trials" 308
BAX pro-apoptotic protein 146
B cell(s) 148
EBV infection 72
markers, lymphoma flow cytometry 176
BCG vaccination 245
intravesical 245, 246
BCL-2 gene 146, 147
Bcl-2 homology (BH) domains 146
Bcl-2 protein 146, 222
overexpression, and inhibitors 147
Bcl-2 protein family 146
BCL-XL 147
BEACOPP regimen 424
BEAM regimen 225
Beck's triad 400
behavior, healthy lifestyle 296, 297, 300
risk factor for cancer 23
behavioral counseling, for healthy lifestyle 96
behavioral therapies, psychiatric disorders 380
benign tumors 164–166, 165
benzene, leukemia causation 86, 86–87
benzodiazepines 350, 351, 381
acute anxiety management 384, 384–386
dependence vs tolerance vs addiction 384
side effects 384–385
withdrawal 384–385
bereavement 388
beta particles 204
Bethesda system, cervical cancer screening 122, 122
bevacizumab (Avastin) 147, 247, 262, 268
benign tumors 396
breast cancer 277
colorectal cancer 276, 277
IFN-α combination 250
NSCLC 277
renal cell carcinoma 277
BH3-only proteins 146, 147
BH domains 146
bias 112, 113
attraction 8
case-control studies 17, 113
experimental studies (single-blinded) 18
information 19
lead time 5, 40, 111, 111, 112
length 111, 112
publication 20
recall 17, 19
reduction, blinding in RCTs 113, 309
selection 19
trend studies 113
bicarbonate 239
bile duct cancer 40, 77
bioinformatics 181
biologic behavior of tumors 184
biomarkers 174
biopsy 167, 194
bipolar disorder, treatment 385
Birt-Hogg-Dubé syndrome 47, 51–52
bisphosphonates 397, 423
cardiovascular disease 296, 326
cardiotoxicity, doxorubicin causing 231, 424
cardiomyopathy 421
cardiac tamponade 400–401
cardiocare emergencies 400–401
carcinogen(s) 81
carcinoembryonic antigen (CEA) 423, 424
carfilzomib
see CD152
CTLA‐4 (CD152)
see CD117
c‐Kit (CD117)
CD20 215
castration 239
cauda equina syndrome 395
CD20 215
CD30 269
CD117 see C‐Kit (CD117)
CD122 249
CD152 see CTLA‐4 (CD152)
CDKNA2A tumor suppressor gene, 102
mutation
on
cell(s) (cancer) 139, 145
chemotherapy principles see chemotherapy
cytomorphologic changes 169
death, after chemotherapy 222, 222
doubling time 220
elimination phase (immune) 244
equilibrium phase 244
escape phase 244
Gompertzian growth 221
in metastasis process 148
resistance to chemotherapy 223
telomerase expression 145
cell cycle 221, 221–222
chemotherapy agents effect radiation effect 224, 224, 226, 226, 227

cell death 146–147
apoptotic see apoptosis
non‐apoptotic mechanisms 147
radiotherapy causing 207

cell survival curves 207, 208, 208
Center for Advancement of Palliative Care (CAPC) 337
Center for Tobacco Products (CTP) 66, 67
Centers for Medicare and Medicaid Services 335
Center to Advance Palliative Care 335
central venous access 198
Cerrobend blocks 215
Certified Specialists in Oncology Nutrition (CSOs) 297

cervical cancer 111, 121

diagnostic methods 121–122
early‐stage, fertility preservation
surgery 366

fertility after 360
HPV and 41, 76, 77, 121
imaging 158
incidence/incidence rate 41, 121
metastatic 158
mortality rates 41

education and income levels 26, 27
international vs US patterns 30
reduced by screening 123

socioeconomic status and 25, 26

precursor lesions 121
screening 111, 121–124
ages for 123, 123–124
Bethesda system 122, 122

global variations 41
goal 121
HPV testing 122, 123, 124
limitations/adverse outcomes 123
recommendations 123, 123–124
relative/absolute benefit 122–123
see also Papanicolaou (Pap) smear
sexual dysfunction after 360
sojourn time 121
squamous cell, in situ hybridization 174

cervical carcinoma in situ (CIN) 111, 121,
122, 124

cetuximab 210, 268, 270
CHAARTED study 239
checkpoint inhibitors, immunotherapeutic see immunotherapy
chemical carcinogens 81, 140–141
"chemobrain" 387
chemoradiotherapy 210, 224
scientific basis for use 220–221
surgery with curative intent with 196
chemoreceptor trigger zone 347, 347
chemotherapy 220–235
adjuvant 223–224, 385
administration 223–224
adverse effects
anaphylactic reactions 402
cognitive changes after 387
delirium 385
febrile neutropenia 393–394
late see late effects of cancer therapy
older people 229
cell cycle activity 224, 226, 229
central venous access 198
classes of agents 224–231
combination of agents 223
concentration–time–effect relationship 220, 221
dose, phase I trials 308
dose dense therapy 223
emergencies related to 401–402

extravasation 401–402
historical aspects 194, 220
hyperthermic intraperitoneal (HIPEC) 196, 197
in increased intracranial pressure 396
inertility due to 365
intraoperative 196
intraperitoneal 196, 197
intravenous 198
neoadjuvant 195–196, 223
Norton–Simon hypothesis 221, 221
older people 328–329
pharmacological principles 221–223
sensitivity in M phase 222
radiotherapy with see chemoradiotherapy
recovery between cycles 220
regional 198
resistance 147, 222–223
routes and schedules 223
Skipper's laws 220
targets 224, 225, 226, 227, 228, 229, 230
apoptotic pathway 147
see also specific chemotherapy classes
timing of delivery 223–224
toxicity 223
prediction in older patients 328–329
chest X‐ray 124, 155, 401
children
anxiety, painful procedures 383
cancer diagnosis, psychological issues 379
cancer pain, psychiatric issues 386
cancer survivors, follow‐up 429
late effects of cancer therapy 429
overweight and obesity 92
physical activity recommendations 93, 93–94
PTSD in 384
sun exposure, melanoma and 100
sunscreen use, sun protection 103
Children's Oncology Group (COG) 429
chimeric antibodies 268
chimeric antigen receptor (CAR) T‐cells 257–258
chloroacetaldehyde 224
chlorpromazine 224
chloroacetaldehyde 224
cholorpromazine 349, 386
cholangiocarcinoma 40, 77
cholesterol 237, 240
chromosomal translocations 174, 176, 177
chromosome(s)
abnormalities, cytogenetics 175–176
in situ hybridization 173
shortening with age 145
chronic lymphocytic leukemia (CLL)
chemotherapeutic agents 225, 228, 229
leukostasis 402
chronic myeloid leukemia (CML) 7
allogeneic HSCT 287, 287
chemotherapeutic agents 225
functional status, older people 326, 326
decline in therapy 430
deficiency, fungi, febrile neutropenia 393, 394
furosemide 397, 397

approach to cancer patients 329
care coordination 328
chemotherapy-associated toxicity, prediction 328–329
diminished physiological capacity/reserve 328
individual vulnerability to therapy 325
multidisciplinary team 328
see also older patients
geriatric syndromes 328
Germany, skin cancer screening 104
germ cell tumors, malignant 366
germ line cancer predisposition 45, 47, 50
Gilbert syndrome 230
Gleason scores 126, 169
glioblastoma 174, 225
Global Alliance for Clean Cookstoves 86
global cancer burden 33–44
access to radiotherapy 37
breast cancer 36, 39
cancer survival 33, 38
cervical cancer 36, 41
colorectal cancer 35, 36, 39
developing countries 33, 34–35
esophageal cancer 35, 36, 41–42
incidence/mortality rates, cancer type 33, 35–36
increase in 3, 41
international data sources 33
liver cancer 35, 36, 40
lung cancer 35, 36, 37–39, 38
oral cavity and pharyngeal cancer 35, 36, 42
prostate cancer 35, 39–40
stomach cancer 35, 36, 41
survival (five-year), by cancer type 38
global tobacco control 68–69
GLOBOCAN website 33
glomerular filtration rate (GFR) 226
glucaease (carboxypeptidase G2) 227
gluocorticoids
hypercaldemia treatment 397, 398
in prostate cancer 240
see also corticosteroids
glucose metabolism, by tumors, PET 159, 160
Goldie–Coldman hypothesis 223
Gompertzian growth 221
gonadectomy 223, 288
gonadotropin–releasing hormone (GnRH) agonists 239
gonadotrophin-releasing hormone (GnRH) antagonist 238, 239
Gorlin syndrome 47, 275
growing of tumors 167–168
graft failure 288
graft-versus-host disease (GVHD) 226, 228, 286, 287, 288–289, 428
acute 288, 289
chronic 288, 289, 428
late effects 428
prevention in alloHSCT 288
sexual dysfunction and 361
treatment 289
granulocyte–macrophage colony-stimulating factor (GM-CSF) 258
granulosa cell tumors, ovarian 366
Gray (Gy) 206
green tea 317
grid-enabled measures (GEM) 415
grief 388, 389
anticipatory 347, 388
complicated 388
gross tumor volume (GTV) 213
group therapy, psychotherapeutic 380–381
growth factor receptor-bound protein 2 (Grb2) 270, 272

Fibrosarcoma 363
flow cytometry 175
lymphoma 175, 175, 176
fludarabine 228–229
fluorescein 36, 41
fluorescence in situ hybridization (FISH) 173, 174
interphase analysis 173–174
fluorochromes 175
18F-fluoro-deoxyglucose (18F-FDG) 160
fluoroscopic simulators 212
fluoroscopy 155, 212
5-fluorouracil (5-FU) 223, 227
fluotamide 239
folate antagonists 226–227
folate metabolism 226, 226, 227
FOLFOX4 therapy 277
follicles, cryopreservation 365
follow-up
alloHSCT survivors 429
imaging examinations 162
recommendations in survivors
breast cancer 422
childhood cancer 429
colorectal cancer 423–424
elderly patients 430
head and neck cancer 427
lung cancer 427–428
lymphoma 425
prostate cancer 423
testicular cancer 426
time interval between assessments 162
Food and Drug Administration (FDA) 316‘deeming rule’ 67
FRO data 413
tobacco regulation 66–67
formaldehyde, exposure 86, 87
formalin-fixed paraffin-embedded (FFPE) tissue 173, 176, 178, 180
‘founder mutations’ 48
Framework Convention on Tobacco Control (FCTC) 62, 68–69
frozen section examination 168
fruits, consumption 95
fulvestrant 238
growth factors, angiogenesis inducers | 147
guaiac-based fecal occult blood test (gFOBT) | 118, 120, 121
guided imagery | 318, 380
GVAX (cancer vaccine) | 258
gynecologic cancers
hereditary syndromes | 47–48, 50
palliative care | 339, 340
sexual dysfunction | 359–360
see also specific cancers

h
hallmarks of cancer | 139, 145, 146, 149, 220
“Hallmarks of Cancer” (Weinberg and Hanahan) | 139
haloperidol | 347, 348, 351, 385
Halsted, William | 193
“Halstedian Theory” | 193
harm reduction, tobacco control | 66
head and neck cancer
follow-up | 427
immunotherapy | 251, 256
late effects of therapy | 426
reconstructive surgery after resection | 197–198
recurrence | 427
survivors | 426–427
HEAL (Health, Eating, Activity, and Lifestyle) study | 296
health inequalities | 10, 23
primacy over trade | 67–68
healthcare inequalities | 29, 30
health insurance | 29
health promotion | 422, 423, 427, 428
healthy lifestyle | 419
ACS guidelines | 92, 93, 293, 294, 296
cancer survivors, implementing | 296–300, 419
diet and exercise behavior | 297, 300
oncologist’s role | 296–297
resources | 300
strategies | 298–299
weight management | 297
prostate cancer | 96
see also diet; physical activity
heart failure, doxorubicin and | 231, 424
Hedgehog (Hh) pathway | 275
Helicobacter pylori infections | 76–77, 81, 142–143
CagA and VacA toxin | 142–143
prevalence and treatment | 41
hematologic emergencies | 402–404
hematologic malignancies | 166
chemotherapy | 220
chromosomal translocations | 176, 177
flow cytometry | 175, 176
immunotherapy, CAR T-cells | 257, 258
interphase FISH in | 174
palliative care access | 339–340, 340
sexual dysfunction | 361
see also leukemia; lymphoma; multiple myeloma
hematopoietic stem cell transplantation (HSCT) | 284–292
allogeneic (alloHSCT) | 284, 285–289, 428–429
complications | 287, 287–289, 428
conditioning regimens | 286–287, 428
donor depletion | 285–286
efficacy | 285
follow-up of survivors | 429
GVHD | 288–289
haploidentical donors | 286
HLA-matched related sibling (MRD) | 286
immediate toxicities | 287, 287
indications | 287, 287
late effects | 428
relapse after | 289, 428–429
stem cell sources | 286
survivors, care | 428–429
autologous (autoHSCT) | 284–285
complications | 285
indications | 284–285, 285
peripheral blood stem cell collection | 284
relapse after | 285
conditioning, agents used in | 225, 228, 286
failure | 288
sexual dysfunction and | 361
transplant-related mortality (TRM) | 286
hepatic artery infusion | 198
hepatic sinusoidal obstruction syndrome (SOS) | 287
hepatitis B virus (HBV) | 40, 73, 74–74, 142
chronic infection | 74, 420
hepatocellular carcinoma and | 40, 73–74, 142
transmission and natural history | 73–74
vaccination, liver cancer prevention | 40, 74
hepatitis C virus (HCV) | 40, 73, 74, 142
chronic infection | 75, 420
hepatocellular carcinoma | 40, 74, 142
transmission and natural history | 74
transmission prevention | 40, 74
hepatocellular carcinoma (HCC) | 77
antiangiogenic therapy | 277
global incidence/mortality | 40
hepatitis B virus and | 40, 73–74, 142
hepatitis C virus and | 40, 74, 142
proton therapy | 217
risk factors | 40, 142
see also liver cancer
toxineosis | 317
HER2 | 271
HER2 gene amplification | 171, 174, 271
HER2 receptor, inhibitor | 271
herbal products | 316, 317
herbicides | 88
hereditary cancer syndromes | 45–53
age at presentation | 45
autosomal dominant inheritance | 45, 46
breast cancer syndromes | 46, 47–48
endocrine tumor syndromes | 46, 51
gastroneuroendocrine syndromes | 46, 48, 50–51
genes involved | 46, 47, 48, 50, 51, 52
genitourinary cancer syndromes | 47, 51–52
genomodermatoses | 47
ovarian cancer syndromes | 46, 47–48
research (ongoing/future) | 52, 52–53
specific syndromes and genes | 46–47
hereditary diarrheal gastritis cancer (HDGC) | 46, 51
hereditary hemorrhagic telangiectasia (HHT) | 46, 50
hereditary leiomyomatosis and renal cell cancer (HLRCC) | 47, 52
hereditary nonpolyposis colon cancer see Lynch syndromes (LS)
hereditary papillary renal cell cancer (HPRCC) | 47, 51
hereditary paraganglioma and phaeochromocytoma | 46, 51
Hh (Hedgehog) pathway | 275
“high-risk individuals” | 45
high-throughput methods
carcinogen screening | 82
DNA sequencing | 178, 179–181, 180
Hispanic people
cancer incidence/mortality | 10, 11–12
overweight and obesity | 93
histology | 166–167
diagnostic uncertainty, reasons | 167
frozen section examination | 168
poorly differentiated malignant tumors | 170, 171
special slide-based procedures | 170–174
histone deacetylase (HDAC) | 275–276
abnormalities, in cancer | 276
inhibitors (HDACi) | 275–276
histones | 275–276
historical aspects
chemotherapy | 194, 220
epidemiology (cancer) | 15
hormonal therapy | 236
radiotherapy | 204
surgical oncology | 193–194
tobacco use | 58
HLA (human leukocyte antigens) | 285–286
Hodgkin’s lymphoma | 73
autoHSCT | 284
chemotherapy | 225, 231, 284
follow-up | 425
late effects of therapy | 424
PD-1 and CTLA-4 inhibitors | 256, 262–263
sexual dysfunction | 361
staging, surgery role reduced | 195
Holliday structures | 144
homologous repair (HR) | 144
hopelessness | 341, 381
hormonal therapy | 236–243
breast cancer see breast cancer
historical aspects | 236
impact on sexual function | 359
prostate cancer see prostate cancer resistance | 240
hormone replacement therapy (HRT) | 39, 361–362
hospital(s)
inpatient acute palliative care unit | 336
inpatient care, hospice service | 337
leaving against medical advice | 387–388
outpatient supportive care | 336
host-response markers | 175
Hounsfield unit (HU) | 156
Hui14.18-II.2 | 249
human epidermal receptor (HER) see epidermal growth factor receptor (EGFR)
human herpesvirus type-8 (HHV-8) | 75, 142
human immunodeficiency virus type-1 (HIV-1) | 73, 75–76, 142, 244, 420
cancers associated | 72, 73, 76
humanized antibodies | 268
human papillomavirus (HPV) | 73, 76, 141
carcinogenesis | 76, 141
cervical cancer and | 41, 76, 121, 122
detection | 41
HPV16 and HPV18 | 76, 122
oral cavity/pharyngeal cancer and | 42
primary prevention and vaccines | 41, 76
testing, cervical cancer screening | 122, 123, 124
types | 76, 122, 141
human T-cell lymphotrophic virus type-1 (HTLV-1) | 73, 76, 142
hydromyotonia | 345
hydroxyurea | 229, 403
hypercalcemia | 397–398
treatment | 397, 397–398

Index
hyperglycemia 271
hyperkalemia 399–400, 400
hyperleukocytosis 402–403
hyperthermic intraperitoneal chemotheraphy (HIPEC) 196, 197
hyperuricemia 399, 400
hyperviscosity 403–404
hypocalcemia 400
hypogonadism 363
hypotension 398
hypoxia, radiation effect and 209, 210
hypoxia-inducible factor-1 (HIF-1) 147–148

i

IARC see International Agency for Research on Cancer (IARC)
ibritumomab 268
idarubicin 231
idelalisib 268, 274
idiopathic pneumonia syndrome (IPS) 288
ifosfamide 224–225
IGF1 271
IGF1R 271
image-guided radiation therapy (IGRT) 209, 213–214
imaging 155–163
clinical settings 160–162
diagnosis and staging 160–161
follow-up 162
response to therapy assessment 161–162
screening 160
justification for radiation use 163
radiation protection 162–163
technical principles 155–160
see also specific modalities
imatine 7
, 180, 268, 269, 271–272
resistance 272
imatine mesylate 271
immune-related response criteria (irRC) 262
immune system, in cancer 244–245, 257, 263
effector cells
autologous HSCT and 284
role in tumor microenvironment 149
immune tolerance 245
immunocytokines 249
"immunoediting theory" 244
immunogenicity, tumor 244
immunoglobulin(s), structure 267
immunoglobulin M (IgM) 403–404
immunohistochemistry 170–171, 171, 172
antigens of diagnostic value 170, 173
“immunological synapse” 250
“immunoperoxidase” procedure 170
immunostimulants
bladder cancer 259
non-specific 245, 249
renal cell carcinoma 262
immunosuppression
EBV-related malignancy 72–73
skin cancer risk factor 102
by tumours 257
immunosurveillance 244
tumor escape 244–245
immunotherapy 244–266
active options, specific cancers 259, 262
adoptive cell therapy 257–258
CAR-T cells 257–258
cytokines 246–248, 249–250, 259
see also interferon-α (IFN-α); interleukin-2 (IL-2)
nonspecific immunostimulants 245, 249, 262
registration trials 246–248, 252–256, 260–261
targeting T-cell cosignaling checkpoints 250–257
adverse reactions 262–263
CTLA-4 inhibition 250–251, 252–256, 257
other agents 257
PD-1/PD-L1 antagonism 251, 252–256, 257, 262–263
specific cancers 262–263
vaccine-based 258–259, 260–261
see also immunostimulants; specific cancers
IMFACT trial 380
incidence (cancer) 16, 16
age-adjusted, trends 4–5
specific cancers in males 7, 7, 8, 8
trends in US 6, 6
delay-adjustment rates 4–5
global 33, 34
developed vs developing countries 33, 35–36
US 6, 6
see also incidence rates
incidence-based mortality (IBM studies) 113
incidence rates (cancer) 16, 16
age-adjusted, trends 8
microbial carcinoagen-associated 77, 78
race and ethnicity 10, 11
specific cancers in males vs females 7, 7, 8, 8
trends in US 6, 6
income levels, cancer mortality and 26, 27–28
infections
after alloHSCT 288
in cancer survivors 420, 424
oncologic emergencies 393–394
infectious agents, cancer causation 10, 72
see also microbial carcinogens
infertility 365, 367, 387
lymphoma patients 424
testicular cancer and 425, 426
inflammation, chronic 143
inflammatory cytokines 143
information bias 19
information collection, PROs 409, 410, 412
information needs, of critically ill patients and caregivers 342
information resources 368
complementary and integrative medicine 316, 317
sexual dysfunction and fertility 368
informed consent 307
information resources
sexual dysfunction and fertility 368
informed consent 307
information on decision-making 246–247
lung cancer screening 125, 125
prostate cancer screening 127–128, 128
in situ hybridization (ISH) 171
Institute of Medicine (IOM) 212, 311, 380, 430
institutional medical culture 337–338
in situ hybridization (ISH) 171
in situ
hybridization (ISH) 171
in situ
hybridization (ISH) 171
inflammation, chronic 143
information bias 19
information collection, PROs 409, 410, 412
information needs, of critically ill patients and caregivers 342
information resources 368
complementary and integrative medicine 316, 317
sexual dysfunction and fertility 368
informed consent 307
information on decision-making 246–247
lung cancer screening 125, 125
prostate cancer screening 127–128, 128
in situ hybridization (ISH) 171
Institute of Medicine (IOM) 212, 311, 380, 430
institutional medical culture 337–338
instrumental activities of daily living (IADLs) 326, 326
insulin-like growth factor-1 (IGF1) 271
insulin-like growth factor-1 receptor (IGF-1R) 271
insulin-like growth factor binding proteins (IGFBPs) 271
Integrated Care Model 340, 341
integrative medicine 315
integrative oncology 315
intensive care unit (ICU) 335, 337
interdisciplinary team see multidisciplinary team
interferon(s) 250
immunotherapy 250
type 1 250
interferon-α (IFN-α) 250
FN-α2b 250
high-dose (HDI) 250, 251, 259
melanoma 246, 250, 251, 259
renal cell carcinoma 247, 262
interleukin-2 (IL-2) 249
immunotherapy 246, 247, 249, 259
combinations involving 249, 249–250
high dose 249, 259, 262
internal consistency 413
International Agency for Research on Cancer (IARC) 20–21, 33, 83
International Classification of Disease 15
International Society for Quality of Life Research 412
interphase fluorescent in situ hybridization (FISH) 173–174
intracranial pressure, increased 396
Intra-treatment Support, tobacco use cessation 63
intravasation, by metastatic cells 148
intravenous fluid 397, 397
iodine-131 215
ionizing radiation 162, 204
adverse effects 162
deterministic and stochastic effects 162
directly or indirectly ionizing 205–206
DNA damage 141
doses, and cancer risk 162
justification for use, and optimization 163
ipilimumab 250, 251, 252, 254, 257, 262
combinations 251, 252
irinotecan 230
isolated tumor cells (ITC) 188
isotopes, therapeutic 214, 215
isotretinoin 104
ixabepilone 230
ixazomib 268, 275

j

juvenile polyposis syndrome (JPS) 46, 50, 51

k

Kaposi sarcoma (KS) 75, 76, 142
Kaposi sarcoma herpesvirus (KSHV) 73, 75, 76, 142
keratinocyte(s) 99
keratinocyte carcinoma 99
see also basal cell carcinoma (BCC); squamous cell carcinoma (SCC)
Kessler, David 66–67
Ketorolac, prostate cancer 240
kidney cancer
hereditary syndromes 47, 51–52
see also renal cell carcinoma (RCC)
kinesin spindle protein inhibitors 230, 231
c-Kit (CD117) 271–272
KRAS gene 147
mutations 141, 180, 272–273
Ku (Ku70/Ku80 heterodimer) protein 144

l

L19-IL-2 249, 249
laparoscopic surgery 198–199, 199
laptinib 268, 271
late effects of cancer therapy 419, 421
breast cancer 421, 421–422
children 429
colorectal cancer 423, 424
head and neck cancer 426
lung cancer 427
lymphoma 424
prostate cancer 422–423
testicular cancer 425–426
men breast cancer 48
cancer incidence rates 6, 6, 7
age-adjusted 8
colorectal cancer 39
lung cancer 37
prostate cancer see prostate cancer race and ethnicity 10, 11
socioeconomic status and 26, 28
cancer mortality rates 7, 7, 10
age-adjusted 10, 10
lung cancer, global 37
melanoma 99
race and ethnicity 10, 12
socioeconomic disparities 26, 27–28
common cancers, by country 33, 34
fertility preservation strategies 367
infertility (cancer-related) 365
sexual arousal disorders 364
sexual desire loss 360
treatment 363
sexual dysfunction in cancer 359, 382
sexual desire loss 360
mental health care
integration into cancer care 380
mind–body practices 318, 380, 384
mental health problems see psychiatric disorders in oncology; psychological impact of cancer

mercaptothiophosphate 228
Merkel cell carcinoma 77, 142
Merkel cell polyomavirus 77, 142
mesna 224
mesothelioma, malignant 83
meta-analyses 20
metabolic emergencies 397–400
metabolic syndrome 428
metal working, bladder cancer and 88
metastases 148–149, 184
distant
follow-up, software solutions 162
imaging to detect 161
inhibitor action/types 274
process (cascade) 148
see also specific organs and cancers
metastasis suppressor genes 149
methylone 345
methylxenate 226–227, 288
resistance 223
O-6-methylguanine-DNA methyltransferase (MGMT) 143, 143, 225
methylenedinitrate 346, 386
meclocapride 347, 348
microarray analysis 177–178
microbial carcinogens 72–80, 141–143
bacterial 76–77, 142–143
biologic mechanisms 72, 73, 141, 142, 143
cancer incidence rates 10, 77, 78
cancer sites associated
parasitic 77
virus 72–76, 74, 75, 141–142
micrometastases 188, 223–224
microsatellite DNA 144
microsatellite instability (MSI) 48, 53, 187
microtubules 229
microtubule targeting agents 224, 229–230
midazolam 351
mind and body practices 316, 318
mindfulness, sexual function and 364
minimal clinically important differences (MCID) 413
minimally invasive surgery (MIS) 198–199
mitazacpine 349, 382, 382
mismatch repair (MMR) 143, 143, 144
genes 48, 50, 144
mitomycin 231
mitosis 221
mitoxantrone 231
modafinil 382, 383, 386
molecular biologic techniques 176–177
molecular imaging techniques 159–160
monoclonal antibodies 267
HER2 overexpression therapy 271
IL-2 conjugation 249
mechanism of action 268–269, 269
types, targets and diseases 268
see also individual monoclonal antibodies
mood stabilizers 385
Moore, Charles 193
MOPP regimen 225
morphine 344, 344–345
mortality 6–7
age standardization 5
all-cause, end-point in screening
evaluation 113
cancer 4, 5
asbestos-related 83
developed vs developing countries 33,
35–36
global 33, 34
at home 339, 340
intensive care units 337
international data sources 33
median age 6
place of 337, 339
racial factors and 339
specific cancers in males vs females 7
exposure, “proof” of causality and 20, 21
leading causes (global) 37, 39, 40, 41
leading causes (US) 3, 5, 7, 23
cancer by age 30
cancer types 23, 34, 37, 39
international comparisons 30
tobacco-related 58, 59, 61, 68, 69
mortality rates 5, 16, 16
age-adjusted 8, 10
long-term trends (1930–2014) 6, 10
men vs women 6, 7, 10, 24
race and ethnicity 10, 12
socioeconomic status and see socioeconomic status (SES)
specific cancers 7, 7, 8
motivational interviewing 63
MPower protocol (WHO) 62
MSH2 gene 48
mTOR 274
mTOR inhibition 147, 240, 262
inhibitor action/types 274
in renal cell carcinoma 277
mTOR kinase domain inhibitors 274
mucosa-associated lymphoid tissue (MALT) lymphoma 77
mucositis 287, 327, 328, 340, 383
chemotherapy-causing 223, 225, 226, 227
Muir-Torre syndrome 46
multidetector-row CT (MDCT) 156
multidisciplinary team 187
geriatric oncology 328
palliative care 335, 336, 337, 339, 340, 351
psychiatric disorders in cancer 386
multikinase inhibitors 272
Multikine 249
multileaf collimators (MLC) 213, 215
multimodal treatment 194, 310
Multinational Association of Supportive Care in Cancer (MASCC) 394, 399
multiple endocrine neoplasia (MEN) type 1 46, 51, 198
type 2 46, 60, 198
multiple myeloma (MM)
autologous HSCT 234
benzene exposure and 86, 87
targeted therapy 276
“multiplex” cancer panels 53
multiplex PCR 178
multislice CT (MSCT) 156
multitargeted small molecule inhibitors 51
murine antibodies (Abs) 267, 269
music therapy 319
mutagen(s), DNA-DNA mismatching 140–141
mutagenicity, Ames test 140
mutation(s) 139, 145
gain-of-function 147
loss-of-function 146, 147
lung cancer 141
mismatch repair (MMR) 48, 50, 144
next-generation sequencing 179–181, 180
passenger and driver 145
point mutations 139–140
solid tumors 145, 5
specific genes, in cancer 143
see also specific genes
MutYH-associated polyposis 50
myelodyplasia 86, 86, 87
therapy-related (t-MDS) 428–429
myelosuppression
alkylating agents 224, 225, 226
antimetabolites 226, 227, 228
leukostasis treatment 403
microtubule targeting agents 229, 230
topoisoeraser inhibitors 230
transfusions/blood products in 420
MYH-associated polyposis 46
n nab-paclitaxel 230
narrative reviews 20
nasopharyngeal carcinoma 142
National Cancer Data Base (NCDB) 4, 184, 188
National Cancer Institute (NCI) 5, 6, 311, 312
Community Oncology Research Program 312
Cooperative Group Program, trials 311
Molecular Analysis for Therapy Choice (MATCH) 312
palliative care 337
PRO data use 413
SEER program 3–4, 6, 8
National Cancer Moonshot 312
National Center for Complementary and Integrative Health (NCCIH) 315, 316
National Center for Health Statistics (NCHS) 4
National Clinical Trials Network (NCTN) 311–312
National Comprehensive Cancer Network (NCCN) 329, 346, 386, 410, 425
lung cancer follow-up 427, 428
National Council on Skin Cancer Prevention 103
National Health and Nutrition Examination Survey 16
National Lung Health and Nutrition Examination Survey 16
National Multidisciplinary Team 316
National Marrow Donor Program (NMDP) 286
National Program of Cancer Registries (NPCR) 3, 4

Memorial Delirium Assessment Scale 351, 352–353
microsatellite instability (MSI) 48, 53, 187
microtubules 229
microtubule targeting agents 224, 229–230
midazolam 351
mind and body practices 316, 318
Index

pain, cancer 343–345, 381
mortality assessment 344
management 344, 344–345, 386
psychiatric issues 383, 386
types 343–345
undertreatment 386
pair production 205
pallophobia 338
palliation minimally invasive surgery 199
surgery 196–197
palliative care 335–358
access to 339–340
barriers 337–339
tumor types 339–340, 340
acute Palliative Care Unit 336
benefits 339
cancer therapy integration 339–340
clinical care pathways to trigger 337
clinicians’ perspectives 339
mobile consultation service 336
in intensive care unit 335, 337
funding, cost avoidance 337, 339
delivery, models 340, 341
communication 340–342
patient characteristics 339, 340
patient/family perceptions 339, 341
programs components 336–337
growth/development 337, 338, 339
supportive framework 337–339, 338
symptoms assessment, management 342–350
anorexia–cachexia syndrome 345–346
assessment tools 342–343, 343
depression and anxiety 347, 350
fatigue 346
nausea 346–347, 347
pain 343–345, 344
terminology and uptake 337, 338
see also end-of-life care; hospice services/medicine
palliative care team 335, 336, 337, 339, 340, 351
Palliative Care Unit (PCU), acute 336
palliative medicine 335–336
models of delivery 340, 341
palliative sedation 351
palillalia 338–339
pamidronate 397, 397
pancreatic cancer
adenocarcinoma, risk 51
alcohol consumption and 17
pipe smokers and 18–19, 19
pancreatitis, hereditary 46, 51
panitumumab 270
panobinostat 268, 276
Papanicolaou (Pap) smear 41, 121–124
erate error 122
frequency, recommendations 123, 124
liquid-based preparations (LBP) 121, 122
method 121–122
optimal sample collection 121–122
relative/absolute benefits 122–123
parenteral feeding 345
PARMA trial 284–285
PARP (poly(ADP-ribose) polymerase) inhibitors 48
particle therapy 216
particle therapy (PTM), outdoor air pollution 84, 85
passenger mutation 145
pathologic evaluation 164–183
cytopathology 168–169, 169, 170
diagnostic intensity lacking 176
frozen section examination 168
histologic study 166–167
macroscopic examination 166
molecular 176–177
staging/grading of tumors 167–168, 185
TNM status assessment 185
tumor classification systems 164–166, 165
tumor markers 174–175
TNM status assessment 185
see also histology; specific techniques
pathologists 164, 166, 167
patient(s) education, cancer survivors 422, 423, 424, 427
functioning, ratings 409
older see older patients
preferences, clinical measures vs 411–412
satisfaction 410
Patient-Centered Outcomes Research Institute (PCORI) 410, 413
patient-centric culture 412
patient-derived prognostic factors 185, 187
tumor types 339–340,
barriers 337–339
components 336–337
classification and types 409,
challenges 415–416
assessing in clinical trials 410
concepts measured, selection 414,
reliability 413
PROMIS 412, 414–415
grid-enabled measures 415
choice, considerations 415–416
PROM (PROM) 409
Patient-Reported Outcomes Measurement Information System (PROMIS) 412, 414
PAX5-associated neoplasia (PABN) 52
PD-1 see programmed death receptor 1 (PD-1)
PDES inhibitors (PDES) 361, 362–363, 364
PDGFRA, gene mutations 51, 271, 272
pediatric cancer see adolescent(s); children Peginteron 246
pegylated interferon-α2b 246, 259
pegylated liposomal doxorubicin (PLD) 231
pelvic floor weakness 359
pembrolizumab 251, 253, 254, 256, 262
pemetrexed 226, 227
penile implant therapy 363
penile injection therapy 363
pentostatin 229
pecrimalial effusion 400
peripheral blood stem cells (PBSCs) 284
peritoneal carcinomatosis 196, 196, 197
personalized medicine, trials 312–313
tertuzumab 271
Pezz-Jeghers syndrome (PJS) 46, 48, 50, 51
pharmacodynamics (PD) 308
pharmacokinetics (PK) 308
pharmacology, chemotherapy 221–223
pharyngeal cancer 19–20, 42
phochromocytoma 46, 51
Philadelphia chromosome 176
phobias 383, 388
phosphoinositide 3-kinase (PI3K) see PI3K pathway
photodisintegration 205
photoelectric effect 205, 206
photon(s) 160, 204, 205
physical activity 92–98, 294–295, 319
ACS guidelines 92, 93, 294, 294–295, 296, 296
adverse events in cancer survivors 297, 300
benefits, in cancer 294–295, 297, 319, 419
cancer prevention 93–94
cancer risk (inverse) relationship 93, 94
cancer survivors, recommendations 419
community action strategies 95–96
dietary interventions with 294
fatigue management 346, 386
lack of, cancer survivors 296
moderate/vigorous, examples 93, 94, 297
prevalence 94
specialized care to improve 297, 300
strategies for healthy lifestyle 298–299
see also healthy lifestyle
phytoestrogens 317
PI3K family 272, 273–274
PI3K pathway 270, 271, 273–274
genes 273, 274
normal function/activation 272, 273–274
targeting (therapeutic) 274
upregulation 274
placental growth factor (PIGF) 276
planning target volume (PTV) 213
plastic surgery 197–198
platelet(s) 403
platelet-derived growth factor (PDGF) 147
platelet-derived growth factor receptor (PDGFR), mutations 51, 271, 272
platelet transfusion 403
platinum drugs 210, 225–226, 230
see also cisplatin
play therapy 384
PLISSIT model 368, 369
point mutations 139–140
point prevalence 16
polymerase chain reaction (PCR) 178
DNA sequence analysis 178–179, 179
isolated tumor cells 188
variants 178, 179
polypharmacy 327, 346

race see ethnicity
radiation 162, 207
- acute toxicity 162, 208
- amount absorbed 205
- biological effects see radiation biology
cancer caused by 83, 84, 86, 87, 140–141, 162
dose deposition 206, 207
interaction with matter 205, 206
ionizing see ionizing radiation
justification for use, optimization 163
natural background radiation 162
particulate 204, 216
physics 204–206
protection 162–163
toxicity 210–212
types 204
radiation biology 162, 206–212
- acute toxicity 208, 209, 210
cell cycle effects 208, 209
cell environmental effects 209–210
cell survival curves 207, 208, 208
cellular repair 207–208
clinical sequelae and toxicity 210–212, 213
- acute and late effects 210
- dose/volume/outcome (QUANTEC) 210, 211, 212
- late consequential effects 210–211
- secondary cancers 211
DNA damage 140–141, 207, 210
- direct and indirect 207
DNA repair after 207–208
- potentially-lethal 208
- sublethal repair 208, 209
dose rate effects 208
early-/late-responding tissues 208–209
fractionation 208–209, 209
- accelerated 209, 209
- hyperfractionation 209, 209
- hypofractionation 209, 209
- interactions with biologic materials 207
- oxygenation, hypoxia 209–210
- radiosensitizers and radioprotectors 210
- survivorship 210–212
radiation-induced cancer 83, 87, 140–141, 162
radiation oncogenesis 396
radiation therapy see radiotherapy
radioactive decay 204–205
radioactive materials, carcinogenicity 81, 83
radiobiology see radiation biology
radiochemotherapy see chemoradiotherapy
radiofrequency pulse (RF pulse) 157
radiography
- chest X-ray 124, 155, 401
- principles 155
radioimmunotherapy 215
radiology see imaging
radionuclide 159, 215
radiopharmaceutical 159
radioprotectors 210
radiosensitivity 208, 209, 210
radiosensitivity 207, 208, 209
methods to increase 210
radiosensitizers 210
radiotherapy 204–219
- access to, global 37
- adjacent organs at risk (OAR) 213
- advautant 212
- beam's eye views 213
- biological aspects see radiation biology
- breast cancer (postoperative) 195–196
- chemotherapy with see chemoradiotherapy
- clinical indication 212
- clinical trials 310
concurrent/sequential systemic therapy 212
curative intent 210, 212
dose 212
dose–volume histogram (DVH) 213
erectile dysfunction after 360, 362
gonadal impairment after 365
gonadal shielding 367
historical aspects 204
image-guided (IGRT) 209, 213–214
immobilization devices 212
increased intracranial pressure 396
infertility due to 365
intensity modulated (IMRT) 210,
215–216, 217
delivery techniques 216
prostate cancer 214
interference/intrafraction motion 213–214
intraoperative (IORT) 206
isocentric 213
late effects in prostate cancer 360, 422, 423
late effects in testicular cancer 425, 426
malignant spinal cord compression 396
modalities 214–217
neutron therapy 217
palliative 210, 212
particle beam therapy 216
patient position 212, 213
protection of normal tissues 213
proton beam 216–217, 217
radiation physics 204–206
second primary malignancy after 423, 424–425
sexual dysfunction after 360, 362, 422
simulator 212–213
systemic targeted radionuclide 215
target volume 213
three-dimensional conformal (3DCRT) 215, 216
toxicology and clinical sequelae 210–212
treatment planning 213
X-rays 204, 205
see also brachytherapy
radium-223 215
radon-222 (radon) 83, 84
radon decay products 83, 86
random error 19
randomized controlled trials (RCTs) 18, 306, 309–310
bias reduction by blinding 113, 309, 413
ClM therapies 318, 319
- designs 309
- eligibility criteria 310
- ethical aspects 307, 309
immunotherapy 246–248
cancer vaccines 260–261
cytokines 246–248, 249
PD-1, CTLA-4 inhibitors 252–256
large 306, 309, 310
limitations and challenges 18, 310
novel therapy vs standard of care 309
placebo-controlled 309
“proof” of causality and 20–21
randomization 309
screening (cancer) evaluation 111, 112–113, 306
breast cancer, mammography 115–116, 116
colorectal cancer 120
end-points 112, 113
invitation for screening 113
prostate cancer 127
stratification factors 309
randomized phase II trials 309
RANKL 398
rapamycin 274
RAPTOR (regulatory associated protein of mTOR) 274
rasburicase 399
Ras/RAS
- activation 270, 272
- gene mutations 272–273
- inhibitors 273
rate difference see attributable risk
rate ratio (RR, risk ratio) 18, 18
R-CHOP regimen 223, 285, 424
reactive oxygen species (ROS) 140, 207, 210
recall bias 17, 19
receptor tyrosine kinases (RTKs) 270, 271, 272, 274
RECIST (Response Evaluation Criteria In Solid Tumors) 161
rectal cancer
- locally advanced 196
- see also colorectal cancer
- registries, cancer 3, 4–5, 15, 16
- regorafenib 272
- rehabilitative services 300, 319
relative risk 5, 18, 18
pipe smoking, cancer mortality 18–19, 19
relative survival 5, 6
improvements and trends 7, 9
relaxation training 318, 380, 384
REMARC checklist 185, 186
renal cell carcinoma (RCC) 52
- clear cell 156
- hereditary 47, 51–52
- immunotherapy 247, 249, 250, 262
cytokines 262
immunostimulants 262
- PD-1, CTLA-4 inhibitors 255, 262–263
targeted therapy 276, 277
VEGF overexpression 277
renal cyst 156
reproductive issues 365–367, 419–420
research
- complementary and integrative medicine 319
- PROs use see patient-reported outcome(s) (PROs)
regulations 307
residual tumor classification 187–188, 196
respiratory depression 344
respiratory emergencies 401
retinoblastoma gene (RB1) 146
- retinoblastoma protein (RB1) 141, 146
- retinoic acid receptor (RAR) 276
retinoid(s), keratinocyte cancer prevention 104
RET oncogene mutation 198
retropertioneal lymph node dissection (RPLND) 425–426
retrospective cohort study 17
retroviruses 142
reverse-transcriptase PCR (RT-PCR) 178, 179
Rindopepimut 260
risk 18
- absolute 18, 19
- attributable see attributable risk
timeframe 5, 6, 162
relative see relative risk
risk-based healthcare 419
risk difference see attributable risk
risk factors for cancer 8, 9, 10, 15–16, 23
behavioral 23
diet see alcohol consumption; diet
measures of association 18–19
older patients, care 329
underweight 293, 327
Union for International Cancer Control (UICC) 184, 185, 187, 188, 195
University of Texas, MD Anderson Cancer Center 337
uric acid 399, 399
urothelial carcinoma, papillary noninvasive 168
US Preventive Services Taskforce (USPSTF)
breast cancer screening 117, 117
cervical cancer screening 123, 123–124
colorectal cancer screening 120, 121
lung cancer screening 125, 125–126
prostate cancer screening 127–128, 128
skin cancer screening 104, 105
uveal melanoma 216
V600E BRAF mutations 273
vaccines/vaccination
cancer, immunotherapy 258–259, 262
hepatitis B virus (HBV) 40, 74
human papillomavirus (HPV) 41, 76
for smoking cessation 67
Vagifem® 362
vaginal atrophy 361
vaginal cancer, sexual dysfunction 360
vaginal dryness 361, 363
vaginal laser therapy 362
vaginal moisturizers 361
validity, PROs 413
vancomycin 394
vandetanib 268
vaptans 398
vardenafil 362, 363
varenicline 64
variant annotation 181
vascular endothelial growth factor (VEGF) 147, 149, 262
antihuman antibody (A4.6.1) 276
inhibitors 270, 276, 277
overexpression, renal cell carcinoma 277
vascular endothelial growth factor receptors (VEGFR) 147
vascular mimicry 148
vegetables, consumption 95
vemurafenib 268, 273
veno-occlusive disease of liver 287
vertebral body metastases 394
vinblastine 229
vinca alkaloids 229
vinorelbine 229
viral infections, after alloHSCT 288
viruses 141
antigenic 245
carcinogenic 72–76, 74, 75, 141–142
visceral pain 343
vismodegib 268, 275
vitamin A 104
vitamin D melanoma prevention 104
recommendations 103
vitamin E 310
vitamin supplements 95
vitrification 365
volume depletion, correction 397
volumetric modulated arc therapy (VMAT) 216
vomiting see nausea and vomiting
von Hippel–Lindau (VHL) syndrome 47, 47, 51
voriconazole 102
vorinostat 276
vulvar cancer, sexual dysfunction 360
vulvovaginal atrophy (VVA) 361, 362
Waldenström’s macroglobulinemia 403, 404
walking, cancer prevention and 93
Warburg phenomenon 159
water arsenic contamination 87
disinfectant by-products, bladder cancer 88
weakness 346
see also fatigue
weight (body weight)
ACS guidelines 92, 293–294
cancer risk and 92–93
healthy 92
loss 93, 294, 297, 327
benefits 93, 294
cancer cachexia 345
management
ACS guidelines 92, 293–294
oncology and primary care providers’ role 297
strategies 298–299
measurement 345
see also obesity; overweight
Western Australia Bowel Health Study 17
White people (US), cancer incidence/mortality 10, 11–12, 29–30
wholegrains, in diet 95
women cancer incidence rates 6, 6
age-adjusted 8
breast cancer see breast cancer
colorectal cancer 39
lung cancer 37
race and ethnicity 10, 11
socioeconomic status and 26, 28
specific cancers 7
mortality rates age-adjusted 10, 10
lung cancer, global 37
race and ethnicity 10, 12
specific cancers 7, 7, 10
common cancers, by country 33, 34
fertility preservation strategies 365–366
infertility (cancer-related) 365
melanoma incidence/mortality 99
sexual arousals disorders 363–364
sexual desire loss 359, 361, 363
sexual dysfunction in cancer 359, 361–362
psychosocial implications 364–365
Women’s Health Initiative (WHI) 361–362
Women’s Healthy Eating and Living (WHEL) study 295
Women’s Intervention Nutrition Study (WINS) 295, 419
World Health Organization (WHO) mortality, indoor air pollution 86
MPOWER protocol, tobacco control 62
nonconventional traditional medicine use 315
Pain Relief Ladder 344, 344
palliative medicine definition 335–336
tobacco, economic effects 60
World Trade Organization (WTO) 68
wortmannin 274
xeroderma pigmentosum 102, 104, 144
X-rays 155, 204, 205
attenuation 155
“breaking energy” 205
cancer association 84, 86, 87, 141, 162
chest 124, 155, 401
diagnostic 155, 205
DNA damage 141
dose deposition 206, 207
interaction with matter/tissue 205, 206
production, radiotherapy 204, 205
zoledronic acid 397, 397